Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|November 19, 2020
Clinical Development of Oncology Products in Japan – the 2nd Largest Market for Innovation
Author(s)IQVIA
*** Thursday, November 19, 2020 | 4:00 pm-5:00 pm EST ***Japan, the second largest market for branded pharmaceuticals and innovation, is driven in part by Oncology with recent advances in genomic analysis technology. In addition, the Japanese market is driven by ongoing regulatory and government initiatives that reward innovation, shifts in population demographics, and increased disease awareness, and identifiable patient populations, amongst other factors. ***On demand available after final airing until Nov. 19, 2021***
Register free:
Event Overview:
Japan is the second largest market for branded pharmaceuticals and innovation and continues to show strong year-on-year growth. Continuous investment in development in Japan is creating many opportunities and growing the potential for multinational biopharma companies.
This is driven in part by Oncology. With recent advances in genomic analysis technology, such as next generation sequencing (NGS), progress is being made in establishing genomic cancer medicine, whereby effective therapies are selected based on the results of genomic analysis of each individual patient.
In addition, the Japanese market is driven by ongoing regulatory and government initiatives that reward innovative product development. Such measures include accelerated review systems such as Sakigake and Conditional Early Approval. Other driving factors are related to shifts in population demographics leading to over 1 million cancer incidence in Japan each year.
Join IQVIA Japan as we discuss opportunities within the Japanese Oncology market and how you can take advantage to increase the value of your Oncology assets.
3 Key take-aways:
- To obtain the information about the Oncology market in Japan
- How to seize the opportunity in this strong potential market.
- Overview and changes in the Japanese Regulatory Environment and international development strategy
Speaker: Alan Thomas, Director, Thought Leadership, IQVIA Japan Group
Time and Date: Thursday, November 19, 2020 | 4:00 pm-5:00 pm EST
On demand available after final airing until Nov. 19, 2021
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5